Threshold Pharmaceuticals, Inc.  

(Public, NASDAQ:THLD)   Watch this stock  
Find more results for THLD
-0.010 (-2.44%)
After Hours: 0.390 -0.010 (-2.50%)
Jun 22, 4:24PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.38 - 0.41
52 week 0.35 - 1.48
Open 0.41
Vol / Avg. 403,067.00/222,680.00
Mkt cap 31.73M
P/E     -
Div/yield     -
EPS -0.30
Shares 71.59M
Beta 3.19
Inst. own 33%
Jul 31, 2017
Q2 2017 Threshold Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jun 13, 2017
Threshold Pharmaceuticals Inc Conference Call to Discuss The Hypoxia and Immunotherapy
May 15, 2017
Q1 2017 Threshold Pharmaceuticals Inc Earnings Release
Mar 27, 2017
Q4 2016 Threshold Pharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '17) 2016
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -92.01% -61.82%
Return on average equity -115.59% -79.34%
Employees 15 -
CDP Score - -


170 Harbor Way Ste 300
United States - Map
+1-650-4748200 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Threshold Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of therapeutic and diagnostic agents that selectively target tumor cells for the treatment of patients living with cancer. It is developing two therapeutic product candidates based on hypoxia-activated prodrug technology: evofosfamide and tarloxotinib. Evofosfamide is designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not in healthy tissues. Tarloxotinib is under investigation in two Phase II proof-of-concept trials: one for the treatment of patients with mutant EGFR-positive, T790M-negative advanced NSCLC progressing on an EGFR TKI, and the other for patients with recurrent or metastatic squamous cell carcinomas of the head and neck. [18F]-HX4 is an investigational Positron Emission Tomography imaging agent for hypoxia to identify and quantify the degree of hypoxia in tumors in vivo.

Officers and directors

Harold E. Selick Ph.D. Chairman of the Board
Age: 62
Bio & Compensation  - Reuters
Wilfred E. Jaeger M.D. Interim Chief Executive Officer, Independent Director
Age: 61
Bio & Compensation  - Reuters
Joel A. Fernandes Vice President - Finance, Controller
Age: 45
Bio & Compensation  - Reuters
Mark Hopkins J.D. Ph.D. Vice President - Intellectual Property and Assistant General Counsel
Bio & Compensation  - Reuters
Kristen Quigley Vice President - Clinical Operations
Age: 45
Bio & Compensation  - Reuters
Tillman Pearce M.D. Chief Medical Officer
Age: 58
Bio & Compensation  - Reuters
Jeffrey W. Bird M.D. Ph.D. Independent Director
Age: 56
Bio & Compensation  - Reuters
Bruce C. Cozadd Independent Director
Age: 53
Bio & Compensation  - Reuters
David R. Hoffmann Independent Director
Age: 70
Bio & Compensation  - Reuters
George G. C. Parker Ph.D. Independent Director
Age: 78
Bio & Compensation  - Reuters